iPSC-Derived Platelet Production for Shelf-Stable Transfusions
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The limited availability and shelf life of donor-derived platelets for transfusions, coupled with the risks associated with their use, necessitates the development of a stable and ethical alternative for platelet production.
Innovation Solution
Utilizing gene-edited human induced pluripotent stem cells (iPSCs) to generate megakaryocytes and platelets ex vivo, leveraging endothelial-to-hematopoietic transition (EHT) and mechanosensitive receptor activation to produce functional platelets, which are immune-compatible and can be stored for extended periods.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If donor-derived platelets are used for transfusions, then immediate therapeutic effect is achieved, but shelf life is limited and availability is constrained
Solution Approach 1:
The patent applies preliminary action by pre-differentiating iPSCs into megakaryocytes and storing them in a dormant state before clinical need. These pre-prepared megakaryocytes can be rapidly expanded and differentiated into platelets when required, eliminating the need for last-minute donor recruitment and enabling extended storage availability while maintaining therapeutic functionality.
2Quantity of substance
If volunteer blood donation is relied upon, then platelet supply is obtained, but demand frequently outstrips supply
Solution Approach 1:
The patent implements self-service by enabling the body's own stem cells (iPSCs) to generate platelets autonomously through controlled differentiation. This self-generating system eliminates dependence on external donor supplies, allowing unlimited production of platelets on-demand to match any demand level without being constrained by donor availability or donation frequency.
3Adaptability or versatility
If gene-edited iPSCs are used to generate megakaryocytes, then immune compatibility is improved, but process complexity increases
Solution Approach 1:
The patent applies parameter changes by modifying specific genetic parameters of iPSCs through gene editing to achieve HLA matching with patients. By altering HLA class I and class II gene expressions, the patent creates immunocompatible megakaryocytes that can be transfused without rejection, while the standardized gene editing protocols and automated differentiation processes help manage the inherent complexity.
Data Source
AI summary
The present disclosure provides for efficient ex vivo processes for generating megakaryocytes and/or platelets from human induced pluripotent stem cells (iPSCs). Cells and platelets generated according to the disclosure in various embodiments are functional and/or more closely resemble the corresponding lineage isolated from peripheral blood, bone marrow, or other tissues. The present invention in some aspects provides isolated cells/platelets and compositions produced by the methods disclosed herein, as well as methods for therapy.